hematologic malignancies
Invivoscribe, Complete Genomics Partner to Develop, Commercialize Oncology Biomarker Tests
The companies will collaborate to develop biomarkers tests for minimal residual disease (MRDs) in research and clinical setting using the DNBSeq sequencer.
Clonal Hematopoiesis Longitudinal Study Reveals High-Risk Mutations for Developing Cancer
A study of blood DNA samples from almost 3,400 adults over 60 years of age highlighted how different clonal mutations affect the risk of developing blood cancers.
A score developed using UK Biobank data can identify patients at high and low risk for blood cancer progression and is starting to be used at Dana-Farber Cancer Institute.
Function Oncology Launches With $28M, Seeks to Transform Precision Cancer Therapy With CRISPR
Premium
The firm unveiled early validation data for its CRISPR-based functional genomics platform, which it hopes to commercialize as another tool doctors can use to individualize cancer care.
Adaptive Biotechnologies, Takeda Partner to Develop Treatments for Lymphoid Malignancies
The multiyear collaboration will use Adaptive's ClonoSeq assay to measure minimal residual disease status as an endpoint for Takeda’s clinical trials.